2023
Enhanced Identification of Hispanic Ethnicity Using Clinical Data
Ochoa-Allemant P, Tate J, Williams E, Gordon K, Marconi V, Bensley K, Rentsch C, Wang K, Taddei T, Justice A, Cohorts F. Enhanced Identification of Hispanic Ethnicity Using Clinical Data. Medical Care 2023, 61: 200-205. PMID: 36893404, PMCID: PMC10114212, DOI: 10.1097/mlr.0000000000001824.Peer-Reviewed Original ResearchConceptsBurden of diseaseHispanic patientsCountry of birthClinical dataHispanic ethnicityNon-Hispanic white patientsSex-adjusted prevalenceChronic liver diseaseHuman immunodeficiency virusDemographic characteristicsElectronic health record dataHealth careHealth record dataPrevalence of conditionsUS health care systemMedicare administrative dataHealth care systemWhite patientsLiver diseaseImmunodeficiency virusSelf-reported ethnicityHigh prevalenceGastric cancerHepatocellular carcinomaVeteran populationTrends, variation, and clinical characteristics of recipients of antiviral drugs and neutralising monoclonal antibodies for covid-19 in community settings: retrospective, descriptive cohort study of 23.4 million people in OpenSAFELY
Green A, Curtis H, Higgins R, Nab L, Mahalingasivam V, Smith R, Mehrkar A, Inglesby P, Drysdale H, DeVito N, Croker R, Rentsch C, Bhaskaran K, Tazare J, Zheng B, Andrews C, Bacon S, Davy S, Dillingham I, Evans D, Fisher L, Hickman G, Hopcroft L, Hulme W, Massey J, MacDonald O, Morley J, Morton C, Park R, Walker A, Ward T, Wiedemann M, Bates C, Cockburn J, Parry J, Hester F, Harper S, Douglas I, Evans S, Goldacre B, Tomlinson L, MacKenna B. Trends, variation, and clinical characteristics of recipients of antiviral drugs and neutralising monoclonal antibodies for covid-19 in community settings: retrospective, descriptive cohort study of 23.4 million people in OpenSAFELY. BMJ Medicine 2023, 2: e000276. PMID: 36936265, PMCID: PMC9951378, DOI: 10.1136/bmjmed-2022-000276.Peer-Reviewed Original ResearchDescriptive cohort studyHigh-risk groupSevere outcomesHigh riskCohort studyHome residentsRisk groupsAntiviral drugsCOVID-19Community settingsMonoclonal antibodiesCasirivimab/imdevimabLow treatment coverageNHS regionProportion of patientsCOVID-19 infectionRoutine clinical dataOpenSAFELY platformUnvaccinated patientsClinical characteristicsLiver diseaseClinical dataTreatment coverageEligibility criteriaPatients
2021
Factors associated with deaths due to COVID-19 versus other causes: population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform
Bhaskaran K, Bacon S, Evans SJ, Bates CJ, Rentsch CT, MacKenna B, Tomlinson L, Walker AJ, Schultze A, Morton CE, Grint D, Mehrkar A, Eggo RM, Inglesby P, Douglas IJ, McDonald HI, Cockburn J, Williamson EJ, Evans D, Curtis HJ, Hulme WJ, Parry J, Hester F, Harper S, Spiegelhalter D, Smeeth L, Goldacre B. Factors associated with deaths due to COVID-19 versus other causes: population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform. The Lancet Regional Health - Europe 2021, 6: 100109. PMID: 33997835, PMCID: PMC8106239, DOI: 10.1016/j.lanepe.2021.100109.Peer-Reviewed Original ResearchNon-COVID deathsCOVID-19 deathsNational death registrationsPrimary care dataOpenSAFELY platformCOVID-19Health Research Oxford Biomedical Research CentrePopulation-based cohort analysisDeath registrationUK primary care dataCare dataPre-existing medical conditionsCOVID-19 mortality riskChronic liver diseaseHistory of cancerUK Medical Research CouncilHealth Data Research UKNational InstituteCOVID-19 mortalityMagnitude of associationMedical Research CouncilNon-white ethnic groupsBiomedical Research CentreCohort studyLiver diseaseUK prevalence of underlying conditions which increase the risk of severe COVID-19 disease: a point prevalence study using electronic health records
Walker JL, Grint DJ, Strongman H, Eggo RM, Peppa M, Minassian C, Mansfield KE, Rentsch CT, Douglas IJ, Mathur R, Wong AYS, Quint JK, Andrews N, Bernal JL, Scott JA, Ramsay M, Smeeth L, McDonald HI. UK prevalence of underlying conditions which increase the risk of severe COVID-19 disease: a point prevalence study using electronic health records. BMC Public Health 2021, 21: 484. PMID: 33706738, PMCID: PMC7948667, DOI: 10.1186/s12889-021-10427-2.Peer-Reviewed Original ResearchConceptsSevere COVID-19Health conditionsElectronic health recordsHigh riskRisk populationsCOVID-19Clinical Practice Research Datalink GOLDSevere COVID-19 diseaseSecondary care recordsChronic kidney diseaseHealth recordsChronic liver diseasePoint prevalence studyBinomial exact confidence intervalsOlder age groupsPublic health interventionsWorking-aged individualsCOVID-19 diseaseWorking-aged adultsUK prevalenceCurrent asthmaLiver diseaseCancer survivorsPoint prevalenceKidney disease